Matthew A. Spear
Plus aucun poste en cours
Profil
Matthew A.
Spear worked as Vice President-Clinical Development at Incyte Corp.
from 2014 to 2016, Head-Oncology & Biotherapeutics at Sumitomo Pharma America, Inc. from 2012 to 2014, and Chief Medical Officer & Senior Vice President at Nereus Pharmaceuticals, Inc. from 2005 to 2011.
He also worked as an Associate Professor at UC San Diego School of Medicine and Keck School of Medicine of USC.
He is currently the Chief Medical Officer at Poseida Therapeutics, Inc. Dr. Spear received his doctorate from Stanford University and his undergraduate degree from The Johns Hopkins University.
Anciens postes connus de Matthew A. Spear
| Sociétés | Poste | Fin |
|---|---|---|
| POSEIDA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 22/04/2022 |
| SANGAMO THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/07/2016 |
| INCYTE CORPORATION | Corporate Officer/Principal | 01/01/2016 |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Corporate Officer/Principal | 01/07/2014 |
Nereus Pharmaceuticals, Inc.
 Nereus Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Nereus Pharmaceuticals, Inc. is a drug discovery and development company pursuing untapped sources of chemical diversity through identifying drug candidates derived from marine microbes. Nereus' discovery portfolio also includes additional drug candidates for oncology, inflammation, and infectious diseases. The company was founded in 1998 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | 01/01/2011 |
Formation de Matthew A. Spear
| The Johns Hopkins University | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| PFIZER, INC. | Health Technology |
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| POSEIDA THERAPEUTICS, INC. | Health Technology |
| INCYTE CORPORATION | Health Technology |
| Entreprise privées | 4 |
|---|---|
Nereus Pharmaceuticals, Inc.
Nereus Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Nereus Pharmaceuticals, Inc. is a drug discovery and development company pursuing untapped sources of chemical diversity through identifying drug candidates derived from marine microbes. Nereus' discovery portfolio also includes additional drug candidates for oncology, inflammation, and infectious diseases. The company was founded in 1998 and is headquartered in San Diego, CA. | Commercial Services |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
